Dear WIPO Re:Search Members,

Pharmaceutical company Provider Members are an essential component of WIPO Re:Search. One of BVGH and WIPO’s goals for 2015 is to recruit more of these companies to WIPO Re:Search. Last month, BVGH sent out hard copies of our 2014 Partnership Hub Report to the CEOs, CMO/CSOs, and heads of CSR of 16 biopharmaceutical and biotechnology companies. Included in these packages was a letter, co-signed by WIPO Director General, Francis Gurry, encouraging the companies to participate in WIPO Re:Search. We have already begun receiving responses from this outreach. If you know of a company with assets of relevance to WIPO Re:Search and an interest in global health, please let Roopa Sriram know and she’ll send our 2014 Report to the company’s decision-makers.

This past month BVGH facilitated the 90th WIPO Re:Search agreement! Congratulations to all our Members on this splendid achievement!

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

Special Announcement

Will you be attending the 2015 BIO International Convention? If so, stop by the sub-Saharan Africa
pavilion that BVGH is organizing. Several WIPO Re:Search Members will be exhibiting at the pavilion. For more information, please email Katy Graef.

---

**WIPO Re:Search Statistics**

![Agreements: 90, Members: 93](image)

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.

---

**Cornerstones of Collaboration**

Four new agreements were finalized last month, including:

**Pfizer** provided Dr. Alexis Kaushansky, a senior scientist at Seattle BioMed, with a compound targeting a host protein. Alexis will test this compound against liver-stage malaria.

A scientist from the **Walter and Eliza Hall Institute of Medical Research** (WEHI) provided Dr. Horacio Bach, Adjunct Professor, Division of Infectious Diseases, **University of British Columbia** (UBC), with recombinant *Plasmodium vivax* proteins involved in the parasite’s entry into red blood cells. Horacio will use his phage display technology to produce antibodies against the proteins, which the WEHI scientist will subsequently test for their ability to block *P. vivax* entry into red blood cells.

---

**Partnership Hub Central**

Roopa Ramamoorthi presented a poster describing WIPO Re:Search and several collaborations at the
6th Annual Consortium of Universities for Global Health (CUGH) Conference held in Boston, MA. While at the meeting, Roopa spoke with researchers from Emory University, Stanford University, and the University of California, San Francisco (UCSF) about current and potential WIPO Re:Search collaboration opportunities.

---

**Funding Announcement**

**E.W. "Al" Thrasher Awards**

The Thrasher Research Fund is open to applications that address significant health problems that affect children in large numbers and offer the potential for practical solutions to these problems. Such solutions should be innovative and have the potential for broad applicability with low financial and/or technical barriers to implementation. Hypothesis-driven research is preferred over exploratory, hypothesis-generating research. Projects with a shorter distance to clinical applicability are given priority.

**Funding amount:** Based on the budgetary needs of the project  
**Funder:** Thrasher Research Fund  
**Deadline:** Applications are accepted on a rolling basis. The Fund has two grant cycles per year.  
**Eligibility:** The Fund is open to applications from institutions worldwide. There are no citizenship or residency requirements.

---

**Member Spotlight**

Founding Provider Member GlaxoSmithKline (GSK) and collaborators published an article in *Scientific Reports*, a Nature Publishing Group journal, that describes a whole-cell phenotypic analysis of its 1.8 million compound diversity library. This library was screened against *T. brucei*, *T. cruzi*, and *L. donovani* in parallel. Potent hits from these screens were assembled into three anti-kinetoplastid sets, which can be provided to lead discovery programs. Click [here](#) to read the paper.

---

**Highlighted Contributions**

Featured this month is a contribution submitted by Eisai to the [WIPO Re:Search Database](#).
E5700: a squalene synthase inhibitor (ID: 427)

Through exploratory research for a treatment for hypolipidemia, E5700 was found to be a novel squalene synthase inhibitor with inhibitory activity of hepatic cholesterol biosynthesis in rats. It was also reported that E5700 possesses activity against *Leishmania amazonensis*, *Toxoplasma gondii* tachyzoites, and *Trypanosoma cruzi*.

For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi or Ujwal Sheth.

### Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 12-17</td>
<td>Keystone Symposium - “The Arthropod Vector: The Controller of Transmission”</td>
<td>Taos, New Mexico</td>
<td>Website</td>
</tr>
<tr>
<td>May 24-28</td>
<td>14th Conference of the International Society of Travel Medicine (CISTM14)</td>
<td>Quebec City, Canada</td>
<td>Website</td>
</tr>
<tr>
<td>June 15-18</td>
<td>2015 BIO International Convention</td>
<td>Philadelphia, Pennsylvania</td>
<td>Website</td>
</tr>
</tbody>
</table>